ArticleCureus2025
A Pathological Complete Response After Pembrolizumab for DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer Enabling Curative Surgery: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a 49-year-old man with initially unresectable, metastatic mismatch repair-deficient colorectal cancer (CRC) who achieved a complete pathological response following neoadjuvant immunotherapy. Metastatic CRC is rarely curable, and complete tumour eradication with standard chemotherapy is exceedingly uncommon. However, deficient mismatch repair/ microsatellite instability-high (dMMR/MSI-H) tumours are uniquely sensitive to immune checkpoint blockade. This patient presented with sigmoid adenocarcinoma with extensive nodal and liver metastatic disease and underwent treatment with pembrolizumab. Restaging imaging demonstrated tumour regression; however, his treatment course was complicated by recurrent small bowel obstructions and the development of a pelvic abscess at the primary cancer site, necessitating interruption of systemic treatment. Multidisciplinary consensus recommended that he should undergo salvage surgical resection. Postoperative pathology surprisingly demonstrated no viable cancer cells in the resected colon, lymph nodes, or hepatic tissue (ypT0N0), confirming a complete pathological response to immunotherapy. Pembrolizumab was resumed postoperatively, and at 10 months post resection, the patient remains disease-free clinically and radiologically. This case demonstrates the potential for PD-1 inhibitor therapy to induce profound remission even in metastatic CRC, potentially enabling long-term disease control. It underscores the importance of routine mismatch repair (MMR) status testing to identify patients who may benefit from immunotherapy and highlights management considerations in patients with exceptional treatment response. This remarkable outcome adds to the growing evidence that a subset of advanced CRC patients can achieve durable remission or even cure with immunotherapy, signalling a shift in the treatment paradigm of these dMMR/MSI-H metastatic CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.